Assignee
EUREKA THERAPEUTICS INC
US·18 granted patents·13 pending applications·85 citations·filing 2009–2025
Top patents by PatentIndex Score
31 records- 0195US10822389B2Antibody/T-cell receptor chimeric constructs and uses thereofEUREKA THERAPEUTICS INC·Filed 2019·Granted Nov 3, 2020·11 cites·22 claims
- 0294US10464988B2Antibody/T-cell receptor chimeric constructs and uses thereofEUREKA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·16 cites·18 claims
- 0394US10098951B2Antibody/T-cell receptor chimeric constructs and uses thereofEUREKA THERAPEUTICS INC·Filed 2017·Granted Oct 16, 2018·17 cites·46 claims
- 0492US10822413B2Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereofEUREKA THERAPEUTICS INC·Filed 2019·Granted Nov 3, 2020·13 cites·27 claims
- 0592US10011658B2Constructs targeting AFP peptide/MHC complexes and uses thereofEUREKA THERAPEUTICS INC·Filed 2017·Granted Jul 3, 2018·14 cites·24 claims
- 0688US11421013B2Antibody/T-cell receptor chimeric constructs and uses thereofEUREKA THERAPEUTICS INC·Filed 2016·Granted Aug 23, 2022·3 cites·20 claims
- 0785US8025879B2Modified glycoproteins and uses thereofEUREKA THERAPEUTICS INC·Filed 2009·Granted Sep 27, 2011·7 cites·6 claims
- 0882US10301388B2Antibody agents specific for human CD19 and uses thereofEUREKA THERAPEUTICS INC·Filed 2017·Granted May 28, 2019·2 cites·19 claims
- 0981US11613573B2Chimeric antibody/T-cell receptor constructs and uses thereofEUREKA THERAPEUTICS INC·Filed 2018·Granted Mar 28, 2023·1 cites·19 claims
- 1081US2024317855A1Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereofEUREKA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1179US2022348629A1Antibody/t-cell receptor chimeric constructs and uses thereofEUREKA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1278US2025361286A1Antibody/t-cell receptor chimeric constructs and uses thereofEUREKA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1376US11447564B2Constructs specifically recognizing glypican 3 and uses thereofEUREKA THERAPEUTICS INC·Filed 2018·Granted Sep 20, 2022·1 cites·25 claims
- 1475US11976105B2Antibody/T-cell receptor chimeric constructs and uses thereofEUREKA THERAPEUTICS INC·Filed 2021·Granted May 7, 2024·0 cites·20 claims
- 1574US2025011463A1Constructs targeting prostate-specific membrane antigen (psma) and uses thereofEUREKA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1670US12479924B2Constructs specifically recognizing Glypican 3 and uses thereofEUREKA THERAPEUTICS INC·Filed 2022·Granted Nov 25, 2025·0 cites·27 claims
- 1769US2021277117A1Constructs targeting afp peptide/mhc complexes and uses thereofEUREKA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1866US11981742B2Antibody agents specific for human CD19 and uses thereofEUREKA THERAPEUTICS INC·Filed 2019·Granted May 14, 2024·0 cites·16 claims
- 1965US11965021B2Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereofEUREKA THERAPEUTICS INC·Filed 2018·Granted Apr 23, 2024·0 cites·23 claims
- 2061US11993661B2Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereofEUREKA THERAPEUTICS INC·Filed 2019·Granted May 28, 2024·0 cites·25 claims
- 2157US2018009892A1Anti-ror1 antibodiesEUREKA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2256US11827672B2Constructs trageting CD22 and uses thereofEUREKA THERAPEUTICS INC·Filed 2019·Granted Nov 28, 2023·0 cites·20 claims
- 2351US2023293687A1T cells and chimeric stimulating receptors and uses thereofEUREKA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2448US2022265715A1Chimeric antigen receptor t cells and uses thereofEUREKA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2548US2018208658A1Constructs targeting afp peptide/mhc complexes and uses thereofEUREKA THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2647US2022323497A1Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereofEUREKA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2747US2020255505A1Cells Expressing Cell Surface Receptors and AntibodiesEUREKA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2845US11673957B2Anti-ROR2 antibodiesEUREKA THERAPEUTICS INC·Filed 2016·Granted Jun 13, 2023·0 cites·14 claims
- 2942US11274157B2Constructs targeting histone H3 peptide/MHC complexes and uses thereofEUREKA THERAPEUTICS INC·Filed 2018·Granted Mar 15, 2022·0 cites·28 claims
- 3039US2020087400A1Constructs targeting psa peptide/mhc complexes and uses thereofEUREKA THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3137US2019382504A1Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereofEUREKA THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EUREKA THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →